These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 2324754

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Antonini A, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA.
    Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
    [Abstract] [Full Text] [Related]

  • 3. [Clinical significance of cramps of the lower extremities in patients with parkinsonism].
    Yu HZ.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):217-8. PubMed ID: 4075911
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK, Rinne JO.
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [Abstract] [Full Text] [Related]

  • 5. Medical treatment of Parkinson's disease.
    Ahlskog JE.
    Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
    [No Abstract] [Full Text] [Related]

  • 6. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
    MacMahon DG, Sachdev D, Boddie HG, Ellis CJ, Kendal BR, Blackburn NA.
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):220-3. PubMed ID: 2182781
    [Abstract] [Full Text] [Related]

  • 7. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS, Herawati L, Wan Y, Movement Disorder Society of Australia Clinical Research and Trials Group, QUEST-AP Study Group.
    Mov Disord; 2009 Jan 15; 24(1):25-31. PubMed ID: 18846551
    [Abstract] [Full Text] [Related]

  • 8. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR, Sage JI, Lang AE, Mark MH.
    Mov Disord; 1994 Mar 15; 9(2):173-7. PubMed ID: 8196678
    [Abstract] [Full Text] [Related]

  • 9. Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.
    Catalán MJ, Escribano PM, Alonso-Frech F.
    Mov Disord; 2017 Apr 15; 32(4):624-625. PubMed ID: 28116835
    [No Abstract] [Full Text] [Related]

  • 10. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A, Sanchez-Ramos J.
    Mov Disord; 1996 May 15; 11(3):327-9. PubMed ID: 8723153
    [No Abstract] [Full Text] [Related]

  • 11. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.
    Schuh LA, Bennett JP.
    Neurology; 1993 Aug 15; 43(8):1545-50. PubMed ID: 8351009
    [Abstract] [Full Text] [Related]

  • 12. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G, Liss C, Reines S, Irr J, Nibbelink D.
    Eur Neurol; 1997 Aug 15; 37(1):23-7. PubMed ID: 9018028
    [Abstract] [Full Text] [Related]

  • 13. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE, Schrag A, Trenkwalder C, Selzer R, Kohnen R, Oertel WH, Poewe W.
    Nervenarzt; 1995 Dec 15; 66(12):933-41. PubMed ID: 8584079
    [Abstract] [Full Text] [Related]

  • 14. What to do when Sinemet fails: Part one.
    Klawans HL.
    Clin Neuropharmacol; 1984 Dec 15; 7(2):121-33. PubMed ID: 6733692
    [No Abstract] [Full Text] [Related]

  • 15. Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
    Olanow CW, Espay AJ, Stocchi F, Ellenbogen AL, Leinonen M, Adar L, Case RJ, Orenbach SF, Yardeni T, Oren S, Poewe W, 006 study group.
    J Parkinsons Dis; 2021 Dec 15; 11(1):177-186. PubMed ID: 33164945
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dyskinesia-Hyperpyrexia Syndrome in Parkinson's disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone.
    Novelli A, Di Vico IA, Terenzi F, Sorbi S, Ramat S.
    Parkinsonism Relat Disord; 2019 Jul 15; 64():352-353. PubMed ID: 31101554
    [No Abstract] [Full Text] [Related]

  • 18. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
    Ahlskog JE, Muenter MD, McManis PG, Bell GN, Bailey PA.
    Mayo Clin Proc; 1988 Sep 15; 63(9):876-86. PubMed ID: 3045435
    [Abstract] [Full Text] [Related]

  • 19. Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.
    Fabbri M, Zibetti M, Beccaria L, Merola A, Romagnolo A, Montanaro E, Ferreira JJ, Palermo S, Lopiano L.
    Eur J Neurol; 2019 Mar 15; 26(3):490-496. PubMed ID: 30347489
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.